Strides Pharma Science Business Operations and Compliance

Author

Reads 11K

A Laboratory Scientist Using a Microscope Inside the Laboratory
Credit: pexels.com, A Laboratory Scientist Using a Microscope Inside the Laboratory

Strides Pharma Science has a robust business operations and compliance framework in place. This framework ensures that the company adheres to regulatory requirements and industry standards.

The company has a strong presence in various markets, including the United States, Europe, and India. Strides Pharma Science has a global footprint with operations in over 100 countries.

Strides Pharma Science has a dedicated team that focuses on business operations and compliance. This team works closely with regulatory bodies and industry associations to ensure that the company remains compliant with all relevant regulations.

The company's commitment to compliance is evident in its robust quality control and quality assurance processes.

Financials

Strides Pharma Science has shown a steady increase in sales over the years, with a compounded sales growth of 14% over the past 10 years.

The company's operating profit margin (OPM) has fluctuated between 4% and 19% in the past 10 years, with an average OPM of 12%.

Here's a breakdown of the company's profit before tax over the years:

The company's net profit has also seen a significant increase, with a compounded profit growth of 206% over the past year.

Profit & Loss

Credit: youtube.com, The INCOME STATEMENT Explained (Profit & Loss / P&L)

Let's dive into the Profit & Loss section of the financials. The company's sales have been steadily increasing over the years, with a 14% compounded growth rate over the past 10 years.

The sales figures for the past 10 years are: Mar 2014 - 1,341m, Mar 2015 - 1,196m, Mar 2016 - 2,861m, Mar 2017 - 2,755m, Mar 2018 - 2,845m, Mar 2019 - 2,178m, Mar 2020 - 2,752m, Mar 2021 - 3,316m, Mar 2022 - 3,070m, Mar 2023 - 3,688m, Mar 2024 - 3,890m, and Mar 2025 - 4,565m.

The company's expenses have also been increasing, but at a slower rate than sales. The expenses for the past 10 years are: Mar 2014 - 1,567m, Mar 2015 - 967m, Mar 2016 - 2,486m, Mar 2017 - 2,228m, Mar 2018 - 2,448m, Mar 2019 - 1,982m, Mar 2020 - 2,338m, Mar 2021 - 2,779m, Mar 2022 - 3,201m, Mar 2023 - 3,544m, Mar 2024 - 3,362m, and Mar 2025 - 3,763m.

Expand your knowledge: Bandhan Bank Fd Interest Rate

Credit: youtube.com, The Basics of a Profit & Loss Income Statement for Small Business Owners

Here's a breakdown of the company's operating profit margins over the past 10 years:

The company's operating profit margin has fluctuated over the years, but it's been generally improving. The highest operating profit margin was 19% in Mar 2015 and Mar 2017, and the lowest was -4% in Mar 2022.

Integrated Filing Financials

Integrated Filing Financials is a game-changer for companies and investors alike. It's a platform where you can find all the Related Party Transactions submitted by the company for the quarter ended March 2025 and thereafter.

To access this valuable information, simply click on the link provided.

Accounting & Shareholding

Let's take a closer look at the company's accounting and shareholding situation.

The company does not have significant contingent liabilities, which means it's not facing any major potential financial risks.

Other income is not affecting the company's ratios, so we can focus on the core financials without worrying about any unusual income fluctuations.

Credit: youtube.com, What is Shareholders' Equity? | Financial Accounting

The company is converting its accounting profit to cash, which is a good sign that it's managing its finances effectively.

Promoters have not sold any shares in the last 90 days, indicating that they're confident in the company's future prospects.

Here are some key points about the company's accounting and shareholding situation:

The company is depreciating its assets at a lower rate, which is contributing to an increase in net profit.

Marketed Drugs

Strides Pharma Science Ltd has a diverse portfolio of commercialized products that help it stay competitive in the market.

One of its notable marketed drugs is a product that Strides Pharma Science Ltd has commercialized.

The company's commercialized product portfolio includes a range of products that cater to various therapeutic areas.

Strides Pharma Science Ltd's commercialized product portfolio is a key factor in its growth and success.

The company's ability to commercialize a wide range of products has enabled it to expand its customer base and increase revenue.

Strides Pharma Science Ltd's commercialized product portfolio includes products that are used to treat a variety of diseases and conditions.

Clinical Trials

Credit: youtube.com, Financials Of Clinical Research Still A Deterrent To PIs

Determine Strides Pharma Science Ltd's go-to-market proposition by gaining insight into their clinical operations, recruitment, and trial strategy.

Strides Pharma Science Ltd has a strong clinical trial presence, as evident from their clinical trials. They have a robust approach to clinical operations.

Their recruitment strategy is a key aspect of their clinical trials, and they seem to be doing it effectively. The company is able to recruit participants for their trials.

Strides Pharma Science Ltd's trial strategy is focused on determining the efficacy and safety of their products. This is crucial for their go-to-market proposition.

Their clinical trial operations are well-organized, allowing them to efficiently manage their trials and gather valuable data. This is a testament to their expertise in the field.

Here's an interesting read: Pharma Brand Strategy Consulting

20 Plus

Strides Pharma Science Ltd has announced plans to commercialize 20+ products, helping investors stay up-to-date with the company's shifting product portfolio.

This means that investors can expect to see changes in the company's product offerings, which can impact financial performance and stock prices.

Identifying which products will be commercialized is crucial for making informed investment decisions, allowing investors to stay one step ahead of the market.

By staying informed about Strides Pharma Science Ltd's commercialization plans, investors can better contend with market fluctuations and make more strategic investment decisions.

Regulatory Compliance

Credit: youtube.com, Quality System Review At Strides Pharma

Regulatory Compliance is a top priority for Strides Pharma Science, ensuring their products meet the highest standards of quality and safety.

Strides Pharma Science has a dedicated team that handles regulatory compliance, working closely with global regulatory agencies to ensure their products are approved for sale in various markets.

The company's expertise in regulatory compliance has enabled them to successfully launch products in over 100 countries worldwide.

Strides Pharma Science has a robust quality management system in place, which is certified to ISO 9001:2015 standards, demonstrating their commitment to excellence in manufacturing and quality control.

For another approach, see: Quality Chemicals Limited

No Objection from Exchanges

Strides Pharma Science has received a No Objection Letter from the stock exchanges, which is a crucial step in ensuring regulatory compliance.

This letter is a formal acknowledgement that the company has met all the necessary requirements and guidelines set by the exchanges.

The company has also informed its members about the Annual General Meeting and the record date for the final dividend for FY25.

Credit: youtube.com, No Objection Statement Application: Guidelines and Procedures

A trading window closure has been announced from July 1, 2025, until 48 hours after the declaration of financial results for the quarter ended June 30, 2025.

This closure is a standard practice to prevent insider trading and maintain market integrity.

The company has also intimated about the superannuation of a Senior Management Personnel, which is a significant event that requires regulatory notification.

In addition, the company has made available the transcript of the Earnings Call pertaining to the Audited Financial Results for the quarter and financial year ended March 31, 2025.

This transparency is essential for investors and stakeholders to stay informed about the company's performance and future prospects.

The company has also published a Newspaper Advertisement announcing the Audited Financial Results for the Quarter and Financial Year ended March 31, 2025.

Consider reading: Jio Financial Blackrock

Under LODR-Restructuring

Under LODR-Restructuring, companies like Strides Pharma Science have been known to divest dormant subsidiaries to streamline their operations.

Strides Pharma Science recently announced the divestment of a dormant step-down wholly owned subsidiary, breaking a seven-month consolidation phase in the process.

Market participation has increased, and experts suggest a buy with a target of Rs 960 in 1-2 months.

Technical indicators support a bullish outlook, and a stop loss is advised at Rs 750 for risk management.

Shareholder Meetings

Credit: youtube.com, Strides Pharma Science Ltd Q1 FY2025-26 Earnings Conference Call

Strides Pharma Science has an upcoming Earnings Call to discuss unaudited financial results for the quarter ended June 30, 2025.

The Company has held a Shareholder Meeting, specifically the 34th Annual General Meeting, where important matters were discussed.

A Postal Ballot was also conducted, where the outcome of the AGM was announced, including a change in Statutory Auditors of a Material Subsidiary in the UK.

Strides Pharma Science regularly updates its investors and analysts through Analyst/Investor Meets, keeping them informed about the Company's progress.

Investor Relations

Strides Pharma Science regularly updates its investors about upcoming events and important announcements. The company has announced an earnings call to discuss its unaudited financial results for the quarter ended June 30, 2025.

The management of Strides will also be attending an investor conference organized by Emkay Global Financial Services Limited on August 12, 2025, at 10:00 hrs in Mumbai. The earnings deck for Q1 FY26 will be the discussion document during these meetings.

Strides Pharma Science also informs its shareholders about important matters, such as the transfer of their equity shares relating to unclaimed dividend to the Investor Education and Protection Fund (IEPF).

Discover more: Jio Financial Services

Analyst Investor Meeting Notice

Credit: youtube.com, What are Investor relations?

Analyst Investor Meeting Notice is a crucial aspect of Investor Relations. Companies often announce such meetings to discuss unaudited financial results with analysts and investors.

These meetings can be scheduled to coincide with key financial milestones, such as the end of a quarter. For instance, Strides Pharma Science announced an Earnings Call to discuss unaudited financial results for the quarter ended June 30, 2025.

Analysts and investors can use these meetings to gain valuable insights into a company's financial performance and future prospects. The format of these meetings can vary, but they often involve a presentation by the company's management team followed by a Q&A session.

For another approach, see: Motilal Oswal Financial Services

Investor Meeting Outcome

Strides Pharma Science Limited recently attended an investor conference organised by Emkay Global Financial Services Limited on August 12, 2025, in Mumbai.

The company's management discussed the earnings deck of Q1 FY26, which was intimated and uploaded on the stock exchange and company website on July 29, 2025.

A wild turkey (Meleagris gallopavo) strides across a sunny grassy field in Southborough, Massachusetts.
Credit: pexels.com, A wild turkey (Meleagris gallopavo) strides across a sunny grassy field in Southborough, Massachusetts.

Strides Pharma Science stock has shown positive momentum, breaking a one-month consolidation in July 2025, and experts suggest a buy for a target of Rupees 975 to Rupees 1030 over the next one to two months.

Analysts advise a stop loss at Rupees 895, and the stock exhibits strength with bullish indicators, having recently reclaimed its 200-DMA.

The company's senior management personnel have been experiencing movement, with an update provided on May 10, 2025.

On a similar theme: 360 One WAM

Employee Benefits

Strides Pharma Science offers an Employee Stock Option Plan (ESOP Scheme) to its employees.

The company has informed the BSE that a meeting of the Board of Directors is scheduled on July 29, 2025, to consider and approve the allotment of shares under the ESOP Scheme.

This allotment is a part of the company's efforts to incentivize and motivate its employees, allowing them to own a stake in the company's success.

The ESOP Scheme is a key component of the company's employee benefits package, providing employees with a financial reward for their hard work and dedication.

Strides Pharma Science has informed the BSE that trading window for Designated Persons of the company is closed from July 1, 2025, and will open after 48 hours post declaration of financial results by the company.

Reporting and Disclosure

Credit: youtube.com, Strides Pharma Science Limited Earnings Conference Call for Q3 FY22

Strides Pharma Science takes its reporting and disclosure seriously. They publish their Business Responsibility and Sustainability Reporting (BRSR) for the financial year ended March 31, 2025.

They also make their unaudited financial results for the quarter ended June 30, 2025, publicly available. This includes a newspaper advertisement announcing the results and an audio recording of an earnings call.

The company believes in transparency and keeping their stakeholders informed about their financial performance.

LODR - Press Release

Strides Pharma Science uses Regulation 30 (LODR) for press releases, which is a requirement for listed companies under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

A press release under Regulation 30 can be used to announce strategic partnerships, like the one with Kenox to expand the nasal spray portfolio for the US market.

Companies must publish press releases under Regulation 30 on their website and in newspapers, as seen in the newspaper advertisement for unaudited financial results for the quarter ended June 30, 2025.

This ensures transparency and timely disclosure of important information to the public and the market.

The press release can also include a schedule of analyst/institutional investor's meet, which provides a platform for discussions and Q&A sessions.

Business Sustainability Reporting

Credit: youtube.com, ESG webinar: Preparing and finalising your Sustainability Report

Business sustainability reporting is a crucial aspect of corporate transparency, and Strides Pharma Science is taking it seriously. They have published their Business Responsibility and Sustainability Reporting (BRSR) for the financial year ended March 31, 2025.

This report is a significant step towards accountability and responsible business practices. It's a great example of how companies can prioritize sustainability and social responsibility.

Strides Pharma Science's BRSR report is a comprehensive document that outlines their performance in various areas, including environmental, social, and governance metrics. It's a must-read for anyone interested in corporate sustainability.

The company's commitment to sustainability is evident in their report, which highlights their efforts to reduce their carbon footprint and promote social welfare.

Here's an interesting read: PS Business Parks

Amendment to Code of Fair Disclosure

Strides Pharma Science has made an amendment to its Code of Fair Disclosure of Unpublished Price Sensitive Information (UPSI).

The company has implemented a strong reporting system, as evident from its Q1 FY 2026 financial results, which showed a revenue of Rs.11,197 million.

Strides Delivers a strong Q1 FY 2026 with Rs.11,197 million Revenue, Rs. 2,181 million EBITDA and Rs. 1,140 million Operational PAT.

On a similar theme: Persistent Systems Revenue

Annual Report Regulation 34(1)

Credit: youtube.com, Reg - 34 - SEBI Listing Regulations- Business Responsibility and Sustainability Report - Part 1

Annual reports are a crucial part of a company's transparency and accountability, and Strides Pharma Science is no exception. They release a Reg. 34 (1) Annual Report for the financial year ending March 31, 2025.

This report provides a comprehensive overview of the company's financial performance and operations. It's a requirement under the Securities and Exchange Board of India (SEBI) regulations.

The report is a detailed document that includes financial statements, management discussion and analysis, and other relevant information. It's a valuable resource for investors, analysts, and other stakeholders.

Strides Pharma Science also releases a Business Responsibility and Sustainability Reporting (BRSR) for the same financial year. This report highlights the company's commitment to sustainability and social responsibility.

The company's annual report is a testament to their commitment to transparency and accountability. It's a must-read for anyone interested in the company's financial performance and operations.

Frequently Asked Questions

What does Strides Pharma Science do?

Strides Pharma Science is a pharmaceutical company that develops and manufactures niche medications, including soft gelatin capsules. It specializes in creating unique, patented formulations to meet global healthcare needs.

Who is the owner of Strides Pharma Science Limited?

The founder and promoter director of Strides Pharma Science Limited is Arun Kumar. He is the key person behind the company's establishment.

Lola Stehr

Copy Editor

Lola Stehr is a meticulous and detail-oriented Copy Editor with a passion for refining written content. With a keen eye for grammar and syntax, she has honed her skills in editing a wide range of articles, from in-depth market analysis to timely financial forecasts. Lola's expertise spans various categories, including New Zealand Dollar (NZD) market trends and Currency Exchange Forecasts.

Love What You Read? Stay Updated!

Join our community for insights, tips, and more.